Abstract: Toxoplasma gondii is a worldwide spread protozoan and is able to infect almost all warm-blood animals. No effective drugs are available clinically on toxoplasmosis. Chinese traditional herbal medicines have provided remedies for many health problems. There exists a possibility that Chinese herbs may provide protection against T. gondii. This work aims to assess the protective efficacy of combined Chinese herbs against T. gondii. We screened five herbal medicines that have different pharmacological effects and combined them into a prescription according to the traditional Chinese medicine compatibility principle. The drug potential and protective efficacy were evaluated through a mouse model by determining the survival time, the parasite load in blood and tissues, the change of cell proportions in blood and histological detection. The results showed that the survival time of mice in the 500 mg Chinese herbs group and sulfadiazine group was significantly longer than that of the PBS control group. Also the parasite load in blood and tissues of 500 mg Chinese herbs and sulfadiazine groups was significantly lower than that of PBS group at 7 days post infection (dpi), which was in accordance with the result of histological detection. Monocyte and neutrophil of infected mice were remarkably increased while lymphocyte was dramatically decreased compared to that of blank group at 7 dpi. The results demonstrated that the 500 mg dosage of our Chinese herbs could slow down the replication of T. gondii and prolong the survival time of mice and could be considered as possible candidate drug against toxoplasmosis.

小鼠模型中研究复方中草药抗弓形虫感染的作用

[1]Bell, A., Ranford-Cartwright, L., 2002. Real-time quantitative PCR in parasitology. Trends Parasitol., 18(8):338-342.

[2]Cinatl, J., Morgenstern, B., Bauer, G., et al., 2003. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet, 361(9374):2045-2046.

[3]Dadimoghaddam, Y., Daryani, A., Sharif, M., et al., 2014. Tissue tropism and parasite burden of Toxoplasma gondii RH strain in experimentally infected mice. Asian Pac. J. Trop. Med., 7(7):521-524.

[4]Fischer, A.H., Jacobson, K.A., Rose, J., et al., 2008. Hematoxylin and eosin staining of tissue and cell sections. Cold Spring Harb. Protoc., 2008(5):pdb.prot4986.

[5]Furtado, J.M., Winthrop, K.L., Butler, N.J., et al., 2013. Ocular toxoplasmosis I: parasitology, epidemiology and public health. Clin. Exp. Ophthalmol., 41(1):82-94.

[6]Innes, E.A., 2010a. A brief history and overview of Toxoplasma gondii. Zoonoses Public Hlth., 57(1):1-7.

[7]Innes, E.A., 2010b. Vaccination against Toxoplasma gondii: an increasing priority for collaborative research? Expert Rev. Vacc., 9(10):1117-1119.

[8]Jongert, E., Roberts, C.W., Gargano, N., et al., 2009. Vaccines against Toxoplasma gondii: challenges and opportunities. Mem. Inst. Oswaldo Cruz., 104(2):252-266.

[9]Kur, J., Holec-Gasior, L., Hiszczynska-Sawicka, E., 2009. Current status of toxoplasmosis vaccine development. Expert Rev. Vaccines, 8(6):791-808.

[10]Lachenmaier, S.M., Deli, M.A., Meissner, M., et al., 2011. Intracellular transport of Toxoplasma gondii through the blood-brain barrier. J. Neuroimmunol., 232(1):119-130.

[11]Li, C., Ying, Q., Su, X., et al., 2012. Development and application of reverse transcription loop-mediated isothermal amplification for detecting live Shewanella putrefaciens in preserved fish sample. J. Food Sci., 77(4): M226-M230.

[12]Machado, A.S., Carneiro, A.C., Bela, S.R., et al., 2014. Biomarker analysis revealed distinct profiles of innate and adaptive immunity in infants with ocular lesions of congenital toxoplasmosis. Mediat. Inflamm., 2014:910621.

[13]Mack, D.G., McLeod, R., 1984. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob. Agents Chemother., 26(1):26-30.

[14]Mordue, D.G., Sibley, L.D., 2003. A novel population of Gr-1⁺-activated macrophages induced during acute toxoplasmosis. J. Leukoc. Biol., 74(6):1015-1025.

[15]Na-Bangchang, K., Karbwang, J., 2014. Traditional herbal medicine for the control of tropical diseases. Trop. Med. Health, 42(2 Suppl.):S3-S13.

[16]National Pharmacopoeia Committee, 2010. Pharmacopoeia of People Republic of China. Chemical Industry Press, Beijing, China (in Chinese).

[17]Noh, E.M., Lee, Y.R., Hur, H., et al., 2011. Radix clematidis extract inhibits TPA-induced MMP-9 expression by suppressing NF-κB activation in MCF-7 human breast cancer cells. Mol. Med. Rep., 4:879-883.

[18]Petersen, E., Schmidt, D.R., 2003. Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options? Expert Rev. Anti-infect. Ther., 1(1):175-182.

[19]Qu, D., Han, J., Du, A., 2013. Enhancement of protective immune response to recombinant Toxoplasma gondii ROP18 antigen by ginsenoside Re. Exp. Parasitol., 135(2):234-239.

[20]Robben, P.M., LaRegina, M., Kuziel, W.A., et al., 2005. Recruitment of Gr-1⁺ monocytes is essential for control of acute toxoplasmosis. J. Exp. Med., 201(11):1761-1769.

[21]Romand, S., Chosson, M., Franck, J., et al., 2004. Usefulness of quantitative polymerase chain reaction in amniotic fluid as early prognostic marker of fetal infection with Toxoplasma gondii. Am. J. Obstet. Gynecol., 190(3): 797-802.

[22]Shen, G., Wang, X., Sun, H., et al., 2016. Seroprevalence of Toxoplasma gondii infection among HIV/AIDS patients in eastern China. Korean J. Parasitol., 54(1):93-96.

[23]Tan, X., Wang, Y.L., Yang, X.L., et al., 2014. Ethyl acetate extract of Artemisia anomala S. Moore displays potent anti-inflammatory effect. Evid. Based Complement. Alternat. Med., 2014:681352.

[24]Yu, H., Huang, B., Zhuo, X., et al., 2013. Evaluation of a real-time PCR assay based on the single-copy SAG1 gene for the detection of Toxoplasma gondii. Vet. Parasitol., 197(3):670-673.

[25]Zheng, B., Lu, S., Tong, Q., et al., 2013. The virulence-related rhoptry protein 5 (ROP5) of Toxoplasma Gondii is a novel vaccine candidate against toxoplasmosis in mice. Vaccine, 31(41):4578-4584.